Plavix, a popular blood-thinning drug, is the target of multiple lawsuits by users and third-party payers, who charge that manufacturers Bristol-Myers Squibb and Sanofi-Aventis US marketed the drug in disregard of its potential health risks.
In five suits filed Monday in federal court in Trenton, N.J., and two filed in October, the plaintiffs claim that the manufacturers promoted Plavix and aspirin together as a regimen for the prevention of blood clots, when safety of that therapy was unknown.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
